Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Al-Sawaf O, Herling CD, Holtick U, Scheid C, Cramer P, Sasse S, von Tresckow B, Tuchscherer A, Fischer K, Eichhorst B, Hallek M, Frenzel LP.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21. No abstract available.

2.

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.

Herling CD, Abedpour N, Weiss J, Schmitt A, Jachimowicz RD, Merkel O, Cartolano M, Oberbeck S, Mayer P, Berg V, Thomalla D, Kutsch N, Stiefelhagen M, Cramer P, Wendtner CM, Persigehl T, Saleh A, Altmüller J, Nürnberg P, Pallasch C, Achter V, Lang U, Eichhorst B, Castiglione R, Schäfer SC, Büttner R, Kreuzer KA, Reinhardt HC, Hallek M, Frenzel LP, Peifer M.

Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.

3.

Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.

Faitschuk E, Hombach AA, Frenzel LP, Wendtner CM, Abken H.

Blood. 2016 Sep 29;128(13):1711-22. doi: 10.1182/blood-2016-01-692046. Epub 2016 Aug 17.

4.

B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.

Knittel G, Liedgens P, Korovkina D, Seeger JM, Al-Baldawi Y, Al-Maarri M, Fritz C, Vlantis K, Bezhanova S, Scheel AH, Wolz OO, Reimann M, Möller P, López C, Schlesner M, Lohneis P, Weber AN, Trümper L; German International Cancer Genome Consortium Molecular Mechanisms in Malignant Lymphoma by Sequencing Project Consortium, Staudt LM, Ortmann M, Pasparakis M, Siebert R, Schmitt CA, Klatt AR, Wunderlich FT, Schäfer SC, Persigehl T, Montesinos-Rongen M, Odenthal M, Büttner R, Frenzel LP, Kashkar H, Reinhardt HC.

Blood. 2016 Jun 2;127(22):2732-41. doi: 10.1182/blood-2015-11-684183. Epub 2016 Apr 5.

5.

Concepts of Chronic Lymphocytic Leukemia Pathogenesis: DNA Damage Response and Tumor Microenvironment.

Frenzel LP, Reinhardt HC, Pallasch CP.

Oncol Res Treat. 2016;39(1-2):9-16. doi: 10.1159/000443820. Epub 2016 Jan 22. Review.

PMID:
26889681
6.

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G.

Int J Cancer. 2015 Nov 1;137(9):2234-42. doi: 10.1002/ijc.29579. Epub 2015 May 12.

7.

miRs-138 and -424 control palmitoylation-dependent CD95-mediated cell death by targeting acyl protein thioesterases 1 and 2 in CLL.

Berg V, Rusch M, Vartak N, Jüngst C, Schauss A, Waldmann H, Hedberg C, Pallasch CP, Bastiaens PI, Hallek M, Wendtner CM, Frenzel LP.

Blood. 2015 May 7;125(19):2948-57. doi: 10.1182/blood-2014-07-586511. Epub 2015 Feb 10.

8.

Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.

Huelsemann MF, Patz M, Beckmann L, Brinkmann K, Otto T, Fandrey J, Becker HJ, Theurich S, von Bergwelt-Baildon M, Pallasch CP, Zahedi RP, Kashkar H, Reinhardt HC, Hallek M, Wendtner CM, Frenzel LP.

Leukemia. 2015 Apr;29(4):981-4. doi: 10.1038/leu.2014.320. Epub 2014 Nov 7. No abstract available.

PMID:
25376373
9.

CD4+ T cell counts reflect the immunosuppressive state of CD4 helper cells in patients after allogeneic stem cell transplantation.

Holtick U, Frenzel LP, Shimabukuro-Vornhagen A, Theurich S, Claasen J, Scheid C, von Bergwelt-Baildon M, Fröhlich H, Wendtner CM, Chemnitz JM.

Ann Hematol. 2015 Jan;94(1):129-37. doi: 10.1007/s00277-014-2166-1. Epub 2014 Aug 15.

PMID:
25118994
10.

Sensitizing protective tumor microenvironments to antibody-mediated therapy.

Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, Hallek M, Chen J, Hemann MT.

Cell. 2014 Jan 30;156(3):590-602. doi: 10.1016/j.cell.2013.12.041.

11.

Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors.

Riabinska A, Daheim M, Herter-Sprie GS, Winkler J, Fritz C, Hallek M, Thomas RK, Kreuzer KA, Frenzel LP, Monfared P, Martins-Boucas J, Chen S, Reinhardt HC.

Sci Transl Med. 2013 Jun 12;5(189):189ra78. doi: 10.1126/scitranslmed.3005814.

12.

B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides.

Schwamb J, Feldhaus V, Baumann M, Patz M, Brodesser S, Brinker R, Claasen J, Pallasch CP, Hallek M, Wendtner CM, Frenzel LP.

Blood. 2012 Nov 8;120(19):3978-85. doi: 10.1182/blood-2012-05-431783. Epub 2012 Aug 27.

13.

Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.

Kuckertz M, Patz M, Veldurthy A, Gehrke I, Claasen J, Frenzel LP, Wendtner CM, Hallek M, Krause G.

Onkologie. 2012;35(7-8):420-6. doi: 10.1159/000341081. Epub 2012 Jul 6.

PMID:
22846973
14.

Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia.

Baer C, Claus R, Frenzel LP, Zucknick M, Park YJ, Gu L, Weichenhan D, Fischer M, Pallasch CP, Herpel E, Rehli M, Byrd JC, Wendtner CM, Plass C.

Cancer Res. 2012 Aug 1;72(15):3775-85. Epub 2012 Jun 18.

15.

Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.

Leskov I, Pallasch CP, Drake A, Iliopoulou BP, Souza A, Shen CH, Schweighofer CD, Abruzzo L, Frenzel LP, Wendtner CM, Hemann MT, Chen J.

Oncogene. 2013 Feb 21;32(8):1066-1072. doi: 10.1038/onc.2012.117. Epub 2012 Apr 9.

16.

Action of novel CD37 antibodies on chronic lymphocytic leukemia cells.

Krause G, Patz M, Isaeva P, Wigger M, Baki I, Vondey V, Kerwien S, Kuckertz M, Brinker R, Claasen J, Frenzel LP, Wendtner CM, Heider KH, Hallek M.

Leukemia. 2012 Mar;26(3):546-9. doi: 10.1038/leu.2011.233. Epub 2011 Sep 2. No abstract available.

PMID:
21886169
17.

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.

Patz M, Isaeva P, Forcob N, Müller B, Frenzel LP, Wendtner CM, Klein C, Umana P, Hallek M, Krause G.

Br J Haematol. 2011 Feb;152(3):295-306. doi: 10.1111/j.1365-2141.2010.08428.x. Epub 2010 Dec 13.

PMID:
21155758
18.

Novel X-linked inhibitor of apoptosis inhibiting compound as sensitizer for TRAIL-mediated apoptosis in chronic lymphocytic leukaemia with poor prognosis.

Frenzel LP, Patz M, Pallasch CP, Brinker R, Claasen J, Schulz A, Hallek M, Kashkar H, Wendtner CM.

Br J Haematol. 2011 Jan;152(2):191-200. doi: 10.1111/j.1365-2141.2010.08426.x. Epub 2010 Nov 23.

PMID:
21091905
19.

Sustained NF-kappaB activity in chronic lymphocytic leukemia is independent of genetic and epigenetic alterations in the TNFAIP3 (A20) locus.

Frenzel LP, Claus R, Plume N, Schwamb J, Konermann C, Pallasch CP, Claasen J, Brinker R, Wollnik B, Plass C, Wendtner CM.

Int J Cancer. 2011 May 15;128(10):2495-500. doi: 10.1002/ijc.25579.

20.

Fibroblasts facilitate the engraftment of embryonic stem cell-derived cardiomyocytes on three-dimensional collagen matrices and aggregation in hanging drops.

Pfannkuche K, Neuss S, Pillekamp F, Frenzel LP, Attia W, Hannes T, Salber J, Hoss M, Zenke M, Fleischmann BK, Hescheler J, Sarić T.

Stem Cells Dev. 2010 Oct;19(10):1589-99. doi: 10.1089/scd.2009.0255.

PMID:
20175666
21.

miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.

Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J, Kutsch N, Krause G, Mayr C, Rosenwald A, Plass C, Schultze JL, Hallek M, Wendtner CM.

Blood. 2009 Oct 8;114(15):3255-64. doi: 10.1182/blood-2009-06-229898. Epub 2009 Aug 19.

22.

Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes.

Frenzel LP, Abdullah Z, Kriegeskorte AK, Dieterich R, Lange N, Busch DH, Krönke M, Utermöhlen O, Hescheler J, Sarić T.

Stem Cells. 2009 Feb;27(2):307-16. doi: 10.1634/stemcells.2008-0528.

23.

Immunological barriers to embryonic stem cell-derived therapies.

Sarić T, Frenzel LP, Hescheler J.

Cells Tissues Organs. 2008;188(1-2):78-90. doi: 10.1159/000118784. Epub 2008 Feb 27. Review.

PMID:
18303241
24.

MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum.

Kuerten S, Kostova-Bales DA, Frenzel LP, Tigno JT, Tary-Lehmann M, Angelov DN, Lehmann PV.

J Neuroimmunol. 2007 Sep;189(1-2):31-40. Epub 2007 Jul 25.

Supplemental Content

Loading ...
Support Center